Vertidiag develops proprietary product until clinical phase I or II.
Acute vestibular syndrome, one of the consequences of peripheral vestibulopathies, is composed of static and dynamic symptoms. Static symptoms include oculomotor and postural deficits, which are usually compensated for in the first few weeks after the attack. Conversely, dynamic symptoms are compensated much less well, or over a very long period of time. Vestibulopathies can also lead to cognitive-spatial impairments.
Pharmacological therapy for vertigo seeks to reduce both static and dynamic deficits, so as to minimize the consequences of acute attacks, and to accompany the progressive restoration of postural, locomotor and gaze stabilization balance. Compounds with anti-vertiginous properties make it possible to significantly reduce some of these symptoms.